Vertex Pharmaceuticals Incorporated and Walgreens Boots Alliance, Inc.: A Comprehensive Revenue Analysis

Vertex vs. Walgreens: A Decade of Revenue Dynamics

__timestampVertex Pharmaceuticals IncorporatedWalgreens Boots Alliance, Inc.
Wednesday, January 1, 201458041500076392000000
Thursday, January 1, 20151032336000103444000000
Friday, January 1, 20161702177000117351000000
Sunday, January 1, 20172488652000118214000000
Monday, January 1, 20183047597000131537000000
Tuesday, January 1, 20194162821000120074000000
Wednesday, January 1, 20206205683000121982000000
Friday, January 1, 20217574400000132509000000
Saturday, January 1, 20228930700000132703000000
Sunday, January 1, 20239869200000139081000000
Monday, January 1, 202411020100000147658000000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Giants: Vertex Pharmaceuticals vs. Walgreens Boots Alliance

In the ever-evolving landscape of the pharmaceutical and retail sectors, Vertex Pharmaceuticals Incorporated and Walgreens Boots Alliance, Inc. stand as titans. Over the past decade, Vertex has seen a meteoric rise in revenue, growing from approximately $580 million in 2014 to nearly $9.9 billion in 2023. This represents an astounding increase of over 1,600%, underscoring Vertex's innovative prowess in the biotech industry.

Conversely, Walgreens Boots Alliance, a stalwart in the retail pharmacy space, has maintained a steady revenue stream, with figures hovering around $120 billion to $140 billion annually. Despite the absence of 2024 data for Vertex, Walgreens continues to show resilience with a projected revenue of $148 billion.

This analysis highlights the contrasting growth trajectories of these two companies, offering insights into their strategic directions and market positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025